Kant-Smits, Kim
Bartels, Bart
Asselman, Fay-Lynn
Veldhoen, Esther S.
van Eijk, Ruben P. A.
van der Pol, W. Ludo
Hulzebos, Erik H. J.
Article History
Received: 16 December 2022
Accepted: 24 February 2023
First Online: 23 March 2023
Declarations
:
: The Medical Research Ethics Committee Utrecht (METC Utrecht) reviewed the study in accordance with the Dutch Medical Research Involving Human Subjects Act (WMO) and other applicable Dutch and European regulations. Based on the requirements of the WMO, the METC Utrecht approved this study. Oral and written informed consent will be obtained when ≥ 16 years old and additional written informed consent will be obtained by the parents or legal representative if the participant is < 16 years old.
: Not applicable.
: LvdP serves on the scientific advisory board for SMA Europe, is a member of the Branaplam data monitoring committee (DMC) for Novartis, provides ad hoc consultancy for Biogen and AveXis (Novartis), and receives research support from the Prinses Beatrix Spierfonds, Vriendenloterij and Stichting Spieren voor Spieren.BB receives research support from Prinses Beatrix Spierfonds, Stichting Spieren voor Spieren and Health Holland, all non-profit foundations. His employer receives fees for SMA-related consultancy activities for Biogen, Novartis, Scholar Rock and Roche.All other authors declare that they have no competing interests.